MyAverix Finance
HK · Healthcare
Biocytogen Pharms (Beijing) (2315)
Biotechnology
Biocytogen Pharms (Beijing) (2315) is listed on HK in the Healthcare sector. Industry: Biotechnology. As of 2026-05-21, reported market cap is $21.92B, P/E ratio is 98.84, net margin is 18.6%. Use this page for a quick overview, then open the MyAverix Finance app for income statements, balance sheet, cash flow, and news.
Key metrics for 2315
Biocytogen Pharms (Beijing) (2315) — FAQ
What is Biocytogen Pharms (Beijing)'s market cap?
Biocytogen Pharms (Beijing) (2315) has a reported market cap of $21.92B (data as of 2026-05-21).
What is 2315's P/E ratio?
The price-to-earnings (P/E) ratio for Biocytogen Pharms (Beijing) (2315) is 98.84 (data as of 2026-05-21).
Does Biocytogen Pharms (Beijing) pay a dividend?
Dividend yield is not available in the current snapshot for Biocytogen Pharms (Beijing) (2315). Check the MyAverix Finance app for the latest dividend data.
What sector is Biocytogen Pharms (Beijing) in?
Biocytogen Pharms (Beijing) (2315) is classified in the Healthcare sector (Biotechnology industry).
What exchange is 2315 listed on?
2315 is listed on HK.
What is Biocytogen Pharms (Beijing)'s net margin?
Biocytogen Pharms (Beijing) (2315) reports a net margin of 18.6% (data as of 2026-05-21).
Full report in the app
Get the full report in the MyAverix Finance app — income, balance sheet, cash flow, ratios, and multi-year trends in one place.